Introduction
============

Autoimmune gastritis, also known as type A gastritis, is characterized by atrophic changes in the fundic mucosa caused by autoimmune mechanisms, such as anti-parietal cell antibodies, that lead to hypergastrinemia and hyperplasia of enterochromaffin-like cells, resulting in complications like hyperplastic polyps, carcinoid tumors, and gastric cancer. Typically, autoimmune gastritis is diagnosed during the medical evaluation of patients with pernicious anemia or type-1 neuroendocrine tumors (NETs) and may be associated with autoimmune thyroid disease or type 1 diabetes mellitus (DM) ([@B1]-[@B9]). No data are available on the prevalence of autoimmune gastritis, which is asymptomatic in the initial stage. In the late stage, autoimmune gastritis may cause pernicious anemia characterized by megaloblastic anemia that can be diagnosed in clinical practice. In Japan, autoimmune gastritis is considered to be a rare disease ([@B10]). In a clinical statistical analysis, Sugihara and Yawata estimated that the prevalence of pernicious anemia caused by autoimmune gastritis was 0.34-0.5 per 100,000 persons in the Japanese population ([@B11]).

Recently, nonalcoholic steatohepatitis (NASH) has been classified as a part of the spectrum of nonalcoholic fatty liver diseases (NAFLD) associated with metabolic syndrome, and the prevalence of NASH has been rapidly increasing worldwide ([@B12]). However, the pathogenesis of NASH is not completely understood. Insulin resistance, inflammatory cytokines, and oxidative stress may play important roles in the development and progression of NASH ([@B13]-[@B15]).

At our institution, we diagnosed autoimmune gastritis in six patients with NASH on the basis of an endoscopic examination between January 2013 and August 2016. Given that autoimmune gastritis is considered a rare presentation, we investigated the association between autoimmune gastritis and NASH in this retrospective study.

Materials and Methods
=====================

Study population
----------------

A total of 1,031 consecutive outpatients ≥30 years of age who underwent esophagogastroduodenal endoscopy at General Medical Center, Kawasaki Medical Hospital between January 2013 and August 2016 were eligible for this study. We retrospectively reviewed the endoscopic findings and laboratory data of 33 patients with NASH, which was confirmed via a liver biopsy; these patients underwent upper gastrointestinal endoscopy for the diagnosis of organic diseases or as part of a healthcare examination at the outpatient clinic.

In this retrospective cross-sectional study, we compared 33 patients with NASH and 144 patients with chronic liver diseases, including 66, 24, 22, 10, 1, and 21 patients with hepatitis C, hepatitis B, autoimmune hepatitis and/or primary biliary cholangitis, non-B/non-C hepatitis, fatty liver, and alcoholic disease, respectively, who underwent upper gastrointestinal endoscopy between January 2013 and August 2016.

Diagnostic criteria
-------------------

In this study, autoimmune gastritis was defined based on the concomitant presence of corpus-predominant atrophic gastritis, fasting hypergastrinemia (\>245.1 pg/mL), histological confirmation of corpus atrophy, and positivity for anti-parietal cell and/or intrinsic factor antibodies, as previously reported ([@B16],[@B17]). The exclusion criteria included the use of nonsteroidal anti-inflammatory drugs, antacids, H2-receptor antagonists, proton pump inhibitors, and antibiotics in the month preceding endoscopy; pregnancy; a history of gastric surgery, systemic diseases such as collagen disease, inflammatory bowel disease, and eosinophilic gastroenteritis; and a history of treatment for *Helicobacter pylori*. Patients with corpus-predominant atrophic gastritis diagnosed by endoscopic findings were tested for gastric autoantibodies, fasting serum gastrin, and *H. pylori* antibody.

A NASH diagnosis was based on the following criteria: (i) alcohol intake ≤20 g/day in women and ≤30 g/day in men; (ii) absence of detectable hepatitis B surface antigen or hepatitis C virus RNA, autoimmune liver disease, drug-induced liver injury, or metabolic liver disease such as Wilson\'s disease and hemochromatosis; and (iii) presence of steatosis (\>5%), steatohepatitis, and inflammation, and hepatocellular ballooning. The liver biopsy findings were evaluated by two expert pathologists, and the features were graded as follows using the NAFLD activity score system proposed by the NASH Clinical Research Network: lobular inflammation (0-3), steatosis (0-3), and hepatocellular ballooning (0-2). The fibrosis stage was assessed according to Brunt\'s classification ([@B18],[@B19]).

The study protocol was in accordance with the 1975 Declaration of Helsinki and approved by the research ethics committee of the study institution. The requirement for informed consent was waived by the research ethics committee due to the retrospective study design.

Statistical analyses
--------------------

Continuous variables at baseline were expressed as the mean with the standard deviation. Comparisons between two groups were performed using Student\'s *t*-test for continuous variables and the χ^2^ test for categorical variables. A p\<0.05 was considered statistically significant. All analyses were performed using JMP software version 13.2 (SAS Institute Japan).

Results
=======

In total, 6 (19.4%; 3 women and 3 men; mean age, 75.3 years) of the 33 patients with NASH were diagnosed with autoimmune gastritis. The prevalence of autoimmune gastritis was significantly higher in patients with NASH than those with other chronic liver diseases (19.4% vs. 2.8%, p=0.002). An analysis of the patient background characteristics revealed no marked differences in the age or sex between the two groups. However, the body mass index, serum aspartate aminotransferase, cholesterol, triglyceride, hemoglobin A1c, serum iron, ferritin, and platelet count were higher in patients with NASH than in those with other chronic liver diseases ([Table 1](#t001){ref-type="table"}).

###### 

Clinical Characteristics of the Study Patients and Biomarkers for NASH and Chronic Liver Disease.

  Characteristics                        NASH             Chronic liver disease      p value
  ----------------------------------- -- ------------- -- ----------------------- -- ----------
  Frequency of autoimmune gastritis      6/33(19.4%)      4/143(2.8%)                0.0026
  Age                                    65.1±11.9        67.6±10.8                  0.2783
  Sex, male                              42%              55%                        0.1784
  BMI (kg/m^2^)                          27.6±4.0         23.2±3.5                   \<0.0001
  Liver cirrhosis                        6.50%            54%                        \<0.0001
  ALT (IU/L)                             52.0±45.5        26.8±30.3                  0.3202
  AST (IU/L)                             43.1±29.7        33.9±21.7                  \<0.0001
  γ-GTP (IU/L)                           60.1±72.6        62.4±95.5                  0.5408
  Total bilirubin (mg/dL)                0.83±0.4         1.0±0.7                    0.0748
  Total cholesterol (ng/dL)              197±40           177±43                     0.0239
  Triglyceride (ng/dL)                   165.4±75.4       117.4±72.0                 \<0.0001
  LDL-C (ng/dL)                          119.4±40.8       104.8±33.7                 0.0757
  HDL-C (ng/dL)                          48.3±20.2        53.5±16.7                  0.0259
  Platelet count (10^4^/µg)              19.4±6.6         15.5±7.1                   0.0021
  Hemoglobin (g/dL)                      13.8±1.5         12.9±2.5                   0.0713
  Hemoglobin A1c                         5.9±0.7          5.4±0.7                    0.003
  Iron (µg/dL)                           122±49.3         84.7±64.3                  0.0116
  Ferritin (ng/dL)                       192.4±283        95.7±128                   0.0319
  γ-Globulin (%)                         17.7±4.4         20.2±5.8                   0.1175

NASH: nonalcoholic steatohepatitis, BMI: body mass index, ALT: alanine aminotransferase, AST: aspartate aminotransferase, γ-GTP: gamma glutamyl transpeptidase, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol

[Table 2](#t002){ref-type="table"} summarizes the characteristics of the six patients with NASH who developed autoimmune gastritis. All patients showed high serum gastrin levels (\>1,500 pg/mL in 5 of the 6 patients). In addition, five patients were positive for anti-parietal cell antibodies (PCAs), whereas one patient who was negative for PCAs was positive for intrinsic factor antibodies. One patient presented with iron-deficiency anemia (hemoglobin \<11 g/dL), but none of the patients developed pernicious anemia. Endocrine cell micronests (ECMs) were found in 4 patients, and *H. pylori* infection was observed in 3 (50%) patients. Although two patients were positive for anti-thyroglobulin antibodies, none of the patients required treatment for thyroid disease. There were 2, 2, and 1 patient with stage 1, 3, and 4 NASH, respectively, among the six patients with autoimmune gastritis. Furthermore, the NASH patients with autoimmune gastritis tended to be older with significantly lower serum ferritin levels than those without autoimmune gastritis. However, no significant differences were observed in other patient characteristics between NASH patients with and without autoimmune gastritis ([Table 3](#t003){ref-type="table"}).

###### 

Clinical Characteristics of the Patients with NASH who Developed Autoimmune Gastritis (n=6).

  --------------------------------------------------------------------------------------------------------------------------------------------------------
      Age, sex   Gastrin\   ECM         PCA\              PGI\      PGII\     PGI/\   IFA   B12\      Folic acid\   Hemoglobin\   *Helicobacter pylori*\
                 (pg/mL)                (Dilution rate)   (ng/mL)   (ng/mL)   PGII          (pg/mL)   (ng/mL)       (g/dL)        antibody
  --- ---------- ---------- ----------- ----------------- --------- --------- ------- ----- --------- ------------- ------------- ------------------------
  1   80F        5,254      \+          20                4.3       6         0.7     \+    252       148           14.3          \+

  2   62F        4,962      \+          80                2         7.4       0.38    \-    362       10.6          10.8          \-

  3   83F        7,800      \+          Negative          6.9       10.1      0.7     \+    176       21.2          11.7          \-

  4   75M        2,368      No biopsy   10                5.2       11.4      0.5     \-    111       8.8           14.9          \+

  5   57M        249        No biopsy   10                15        3.5       4.3     \-    486       8.1           13.7          \+

  6   84M        1,641      \+          10                76.4      10.4      7.3     \-    890       7.9           11.8          \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------

NASH: nonalcoholic steatohepatitis, ECM: endocrine cell micronest, PCA: anti-parietal cell antibody, PGI: pepsinogen I, PGII: pepsinogen II, IFA: intrinsic factor antibody, M: male, F: female

###### 

Clinical Characteristics and Biomarkers of Patients with NASH with and without Autoimmune Gastritis.

  Characteristics                   Autoimmune gastritis (+)      Autoimmune gastritis (-)      p value
  ------------------------------ -- -------------------------- -- -------------------------- -- ---------
  Age                               73.5±11.0                     63.1±11.4                     0.0426
  Sex, male                         66%                           60%                           0.7616
  BMI (kg/m^2^)                     26.4±2.1                      27.8±4.3                      0.7451
  Stage (0/1/2/3/4)                 0/2/0/3/1                     1/5/4/10/5                    0.6207
  Grade (0/1/2/3)                   0/1/4/1                       0/11/12/2                     0.4139
  Diabetes mellitus                 50%                           56%                           0.7912
  Hypertension                      33.30%                        52%                           0.4071
  Dyslipidemia                      100%                          92.00%                        0.3447
  ALT (IU/L)                        33.6±12.5                     49.5±30.9                     0.4092
  AST (IU/L)                        41.1±15.0                     38.4±15.6                     0.745
  γ-GTP (IU/L)                      42.3±18.0                     59.1±71.0                     0.7075
  Total cholesterol (ng/dL)         201±22.8                      197±43.5                      0.617
  Platelet count (10^4^/µg)         20.2±7.4                      19.4±6.5                      0.7451
  Hemoglobin (g/dL)                 13.1±1.7                      14.0±1.5                      0.3468
  HOMA-IR                           2.4±0.9                       4.3±2.6                       0.126
  Iron (µg/dL)                      114±60                        124±47                        0.7754
  Ferritin (ng/dL)                  48.6±50.8                     228±306                       0.0076
  γ-Globulin                        16.4±2.5                      18.1±5.0                      0.6015
  Antinuclear antibody              16%                           25%                           0.6567
  Leptin (ng/dL)                    11.4±5.8                      13.5±8.4                      0.824
  Adiponectin (µg/mL)               6.2±1.8                       6.1±2.3                       1
  High-sensitivity CRP (mg/dL)      0.16±0.1                      0.13±0.15                     0.2299
  WFA+M2BP (C.O.I)                  1.3±0.9                       1.6±0.9                       0.5711
  Type-4 collagen 7S (ng/mL)        4.8±1.0                       4.9±2.1                       0.8623

NASH: nonalcoholic steatohepatitis, NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, ALT: alanine aminotransferase, AST: aspartate aminotransferase, γ-GTP: gamma glutamyl transpeptidase, HOMA-IR: homeostatic model assessment-insulin resistance, CRP: C-reactive protein, WFA+M2BP: Wisteria floribunda agglutinin Mac-2 Binding protein

Case 1 is described below to illustrate NASH with autoimmune gastritis. A histological examination of the transcutaneous liver biopsy sample after hematoxylin/eosin and Azan staining revealed lobular inflammation, hepatocellular ballooning degeneration, and perisinusoidal fibrosis as well as the presence of macrovesicular hepatocellular steatosis. Consequently, the patient was diagnosed with NASH (Brunt\'s classification: stage 1, grade 1) ([Fig. 1](#g001){ref-type="fig"}). An endoscopic examination revealed typical findings of corpus-predominant atrophic gastritis ([Fig. 2](#g002){ref-type="fig"}). The biopsy specimens showed mild inflammation and severe atrophy in the corpus mucosa. However, no inflammation or atrophy was observed in the pyloric mucosa. In [Fig. 3](#g003){ref-type="fig"}, the upper right panel shows the presence of several ECMs in the corpus mucosa, and the lower right panel shows positive chromogranin staining.

![Histological examination of transcutaneous liver biopsy after Hematoxylin/Eosin (a, ×10) (b, ×20) and Azan (c, ×20) staining showing lobular inflammation, hepatocellular ballooning degeneration, and perisinusoidal fibrosis as well as the presence of macrovesicular hepatocellular steatosis. Consequently, the patient was diagnosed with nonalcoholic steatohepatitis (NASH; Brunt's classification, stage 1, grade 1).](1349-7235-58-2907-g001){#g001}

![Endoscopic examination reveals typical endoscopic findings of corpus-predominant atrophic gastritis (a and b, corpus; c, antrum).](1349-7235-58-2907-g002){#g002}

![Histological examination reveals mild inflammation and severe atrophy in the corpus mucosa (a, ×40). Several ECMs are noted in the corpus mucosa (b, ×40), but the pyloric mucosa appears normal (c, ×40). In another specimen of the corpus mucosa, ECMs are stained by chromogranin A (d, ×40).](1349-7235-58-2907-g003){#g003}

Discussion
==========

This is the first study to report a positive association between NASH and autoimmune gastritis, which is a critical condition because it causes hypergastrinemia and can lead to pernicious anemia, gastric cancer, and gastric NETs.

In the current retrospective cross-sectional study, the presence of autoimmune gastritis was determined by assessing endoscopic images obtained from 177 patients with chronic liver disease who underwent upper gastrointestinal endoscopy. Initially, autoimmune gastritis was suspected based on endoscopic findings of corpus-predominant atrophic gastritis, which was diagnosed from the presence of ECMs and the results of testing for anti-parietal cell and anti-intrinsic factor antibodies, serum gastrin, and gastric tissue samples. Autoimmune gastritis was defined as the presence of corpus-predominant atrophic gastritis with hypergastrinemia in the presence of anti-PCAs and/or ECMs in the corpus mucosa.

One patient in the current study cohort presented with iron-deficiency anemia. Achlorhydria as a result of autoimmune gastritis is associated with iron-deficiency anemia. Thus, the recognition of autoimmune gastritis is important in patients with refractory iron-deficiency anemia ([@B20],[@B21]).

Autoimmune gastritis may be associated with autoimmune thyroid disease or type 1 DM. However, an association between autoimmune gastritis and NASH was not reported previously. Kutsuma et al. reported that overweight Japanese men had low pepsinogen I levels and a low pepsinogen I/II ratio ([@B22]). These intriguing findings may be applicable to not only patients with type A gastritis but also those with *H. pylori*-positive type B gastritis. A study in northern Sweden found that atrophic corpus gastritis was more common among obese patients (body mass index ≥30 kg/m^2^) and in patients with DM, particularly men 35-44 years of age ([@B23]). NASH may be associated with autoimmune gastritis, as it is common in patients with obesity and DM. However, the underlying mechanism is not completely clear. NASH can emerge in the presence of various clinical conditions, including insulin resistance and oxidative stress as well as other conditions that affect iron levels and alter intestinal bacterial flora ([@B13]-[@B15],[@B24],[@B25]). In some patients, autoimmune factors may cause NASH. Furthermore, in autoimmune gastritis, the barrier of the gastric wall or the intestines is impaired because of decreased gastric acid levels, which alters the intestinal bacterial flora and causes leaky gut syndrome ([@B26]), thereby promoting the flow of endotoxins into the portal vein and eventually leading to NASH.

The diagnosis of autoimmune gastritis is challenging prior to the onset of anemia, which occurs in advanced-stage disease, unless autoimmune gastritis is suspected based on reversed atrophic-type gastritis on upper endoscopy or altered gastrin levels. In the current study, the patients with NASH were older and had lower ferritin levels, which are usually elevated in NASH, than those without NASH ([@B27]). Thus, autoimmune gastritis in patients with NASH can be screened by measuring gastrin and ferritin levels. The present study is limited by the small number of cases and poor understanding of the underlying pathogenesis.

Conclusion
==========

Autoimmune gastritis is common in patients with NASH. The rapid increase in the prevalence of NASH in Japan might lead to an associated increase in the incidence of autoimmune gastritis. The early diagnosis of autoimmune gastritis may prevent pernicious anemia due to vitamin B12 deficiency or peripheral neuropathy and may help identify patients at high risk for gastric cancer or NETs.
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